Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier to anthracycline use in heavily pretreated R/R AML HOUSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.